We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Molzym GmbH

Molzym develops innovative solutions focused on new processes enabling and facilitating the molecular diagnosis of in... read more Featured Products: More products

Download Mobile App




Direct Molecular Detection of Bloodstream Infection Evaluated

By LabMedica International staff writers
Posted on 02 Aug 2016
Blood culture is the current gold standard for detecting bacteria in blood, requires at least 24 to 48 hours and has limited sensitivity if obtained during antibiotic treatment of the patient. More...
Severe sepsis is sepsis associated with organ dysfunction, hypoperfusion, or hypotension.

Rapid diagnosis and appropriate antimicrobial therapy are of major importance to decrease morbidity and mortality in patients with blood stream infections (BSI). Sepsis, severe sepsis and septic shock are associated with high mortality, ranging from 20% to 60 % depending on severity and underlying disease. Septic shock is the persistence of hypotension and perfusion abnormalities despite adequate resuscitation therapy.

Scientists led by those at VU University Medical Center (Amsterdam, The Netherlands) carried out a prospective multicenter study to clinically evaluate the application of a commercial universal molecular test directly on whole blood. In total 236 samples from 166 patients with suspected sepsis were included in the study. The molecular test results were compared to blood culture, the current gold standard for detecting BSI. Because blood cultures can give false-negative results, the team performed an additional analysis to interpret the likelihood of bloodstream infection by using an evaluation based on clinical diagnosis, other diagnostic tests and laboratory parameters.

Fresh EDTA blood was divided into two aliquots of 1 mL and processed according to the SepsiTest protocol (PCR-ST, Molzym, Bremen, Germany). The SepsiTest assay selectively degrades human DNA, before isolation of the microbial DNA. SepsiTest can provide a positive or negative result within four hours and needs additional sequencing to identify the microorganism, which takes another two to three hours if sequencing is available in the laboratory.

The clinical interpretation of results defined the detected organism to be contaminants in 22/43 positive blood cultures (51.2 %) and 21/47 positive PCR-ST results (44.7 %). Excluding these contaminants resulted in an overall sensitivity and specificity of the PCR-ST of 66.7% and 94.4%, respectively. Of the 36 clinically relevant samples, 11 BSI were detected with both techniques, 15 BSI were detected with PCR-ST only and 10 with blood culture only. Therefore, in this study, SepsiTest detected an additional 71 % BSI compared to blood culture alone. The majority of detected microorganisms were staphylococci in both blood culture and PCR-ST.

The authors concluded that overall, PCR-ST results may influence the administration of adequate antimicrobial therapy and diminish patient’s morbidity and mortality. Although the SepsiTest PCR directly on blood is a promising technique, the input volume of blood should be increased to lower sampling error, and a faster procedure to identify the microorganism is of importance. The study was published on June 30, 2016, in the journal BMC Infectious Diseases.

Related Links:
VU University Medical Center
Molzym


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.